Agents that enhance cholinergic transmission or activate muscarinic acetylcholine receptors have been developed to ameliorate the loss of cognitive function in patients with Alzheimer's disease (AD) and have been suggested to have modest success in slowing disease progression. The development of selective orthosteric agonists for the M1 receptor has been relatively unsuccessful due to the high conservation of the orthosteric binding site across all five muscarinic receptor subtypes (M1-M5). We have discovered several different classes of allosteric modulators of G protein-coupled receptors: allosteric agonists and positive allosteric modulators (PAMs). Our preliminary data suggest that targeting allosteric sites on the receptor is a viable approach for developing highly selective activators of the M1 muscarinic acetylcholine receptor, since these allosteric sites are thought to be less conserved between receptor subtypes. Furthermore, evidence suggests that there are multiple allosteric binding sites on the M1 receptors. However, the locations of these secondary binding sites and the residues that are critical for binding have not been fully characterized. We propose to determine and characterize the location of the allosteric binding sites for BQCA (PAM), and TBPB and VU0357017 (allosteric agonists) using a combination of chimeric receptors and site-directed mutagenesis. We will then determine if these compounds display agonist-directed signaling, a phenomenon in which there is selective activation of particular signaling cascades, downstream of the M1 muscarinic acetylcholine receptor in cortical tissue slice preparations. Furthermore, we will determine the ability of these compounds to alter the electrophysiological properties of pyramidal neurons in the medial prefrontal cortex using whole-cell patch clamp recordings. In addition, we will utilize a mouse model of AD to try to understand how muscarinic receptor activation might be altered in pathological states. These studies will provide greater insight into the mechanism of action of allosteric ligands at the M1 receptor and potentially the possibility of selectively targeting activation of particular signaling cascades that are beneficial for disease treatment, while avoiding the activation of other cascades that may result in dose-limiting or adverse side effects.

Public Health Relevance

Studies of the function of muscarinic receptors in the medial prefrontal cortex may lead to an increased understanding of the changes in muscarinic receptor signaling that contribute to the cognitive symptoms of Alzheimer's disease. The resuts of these studies will have important implications for the development of novel approaches to treat Alzheimer's disease and other neurodegenerative diseases.

National Institute of Health (NIH)
National Institute of Neurological Disorders and Stroke (NINDS)
Postdoctoral Individual National Research Service Award (F32)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1-F03B-H (20))
Program Officer
Corriveau, Roderick A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Vanderbilt University Medical Center
Schools of Medicine
United States
Zip Code
Gregory, Karen J; Nguyen, Elizabeth D; Malosh, Chrysa et al. (2014) Identification of specific ligand-receptor interactions that govern binding and cooperativity of diverse modulators to a common metabotropic glutamate receptor 5 allosteric site. ACS Chem Neurosci 5:282-95
Yin, Shen; Noetzel, Meredith J; Johnson, Kari A et al. (2014) Selective actions of novel allosteric modulators reveal functional heteromers of metabotropic glutamate receptors in the CNS. J Neurosci 34:79-94
Rook, Jerri M; Noetzel, Meredith J; Pouliot, Wendy A et al. (2013) Unique signaling profiles of positive allosteric modulators of metabotropic glutamate receptor subtype 5 determine differences in in vivo activity. Biol Psychiatry 73:501-9
Gregory, Karen J; Noetzel, Meredith J; Niswender, Colleen M (2013) Pharmacology of metabotropic glutamate receptor allosteric modulators: structural basis and therapeutic potential for CNS disorders. Prog Mol Biol Transl Sci 115:61-121
Noetzel, M J; Gregory, K J; Vinson, P N et al. (2013) A novel metabotropic glutamate receptor 5 positive allosteric modulator acts at a unique site and confers stimulus bias to mGlu5 signaling. Mol Pharmacol 83:835-47
Digby, Gregory J; Noetzel, Meredith J; Bubser, Michael et al. (2012) Novel allosteric agonists of M1 muscarinic acetylcholine receptors induce brain region-specific responses that correspond with behavioral effects in animal models. J Neurosci 32:8532-44
Gregory, Karen J; Noetzel, Meredith J; Rook, Jerri M et al. (2012) Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships. Mol Pharmacol 82:860-75
Noetzel, Meredith J; Rook, Jerri M; Vinson, Paige N et al. (2012) Functional impact of allosteric agonist activity of selective positive allosteric modulators of metabotropic glutamate receptor subtype 5 in regulating central nervous system function. Mol Pharmacol 81:120-33